BioSpace News Archive

MB-204 is the Company’s lead compound with potential application to the neurological diseases of depression & anxiety, Alzheimer’s, ADHD and non-neurological diseases such as cancer and non-alcoholic steatohepatitis.

The Genetic Testing Service market was valued at US$ 9,546.2 million in 2019 and is expected to grow at a CAGR of 11.7% from 2020 to 2027 to reach US$ 22,701.8 million by 2027.

The Track and Trace Solutions market was valued at US$ 1,728.3 million in 2018 and it is projected to reach US$ 6,049.0 million by 2027; it is expected to grow at a CAGR of 15.3% from 2018 to 2027.

A first-of-its-kind study published today in AACC’s Clinical Chemistry journal shows that a new protocol for coronavirus testing can increase clinical labs’ testing capacity without sacrificing accuracy

OpenEye Scientific, an industry leader in computational molecular design, has named Dr. Giovanna Scapin as its newest addition to its Board of Directors.

TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Company’s common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions.

Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma (rGBM).

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has received conditional listing approval from the NYSE American LLC stock exchange.

The market is being valued in terms of sales from products catering to deformities, trauma, sports medicine, spine, and smart implants.

The demand within the global medical laboratories market is slated to multiply over the next decade.